Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Mologen AG. (10/21/16). "Press Release: Successful Completion of Capital Increase with Substantial Oversubscription [Not for USA, Australia, Canada or Japan, et al.]".

Organisations Organisation Mologen AG
  Group Mologen (Group)
  Organisation 2 TowerCrest LLC (CN)
Products Product lefitolimod (MGN1703)
  Product 2 EnanDIM® technology
Index terms Index term Mologen–SEVERAL: investment, 201609–201610 capital increase €13.6m 11.316m common shares at €1.2/share (raising no. of existing shares by up to 50%)
  Index term 2 Mologen–Global Derivative Trading: credit, 201609– convertible bond with total nominal value of €2.54m by largest investor GDT
Persons Person Söhngen, Mariola (Proteome Sciences 202009– CEO before Convert Pharmaceuticals + Mologen + Paion)
  Person 2 Nickolaus, Claudia (Mologen 201407– Head Investor Relations)
     


   
Record changed: 2019-06-09

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Mologen (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top